Efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomitting in patients with haematological malignancies

Efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomitting in patients with haematological malignancies - Efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomitting in patients with haematological malignancies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005733

Enrollment

Registered

2011-06-17

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

haematological malignancies

Interventions

Palonosetron on day 1 Granisetron on day 1 to 4

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)over 20 years old 2)determinded of haematological malignancies 3)recive over MEC chemotherapy until 4 days 4)able to fact-finding on the spot 5)oral administration 6)PS(ECOG):0-2 7)adequate organ function 8)first-line chemotherapy or over 12 month chemo-free 9)written informed concent

Exclusion criteria

Exclusion criteria: 1)hypersensitivity for palonosetron or other 5-HT3 receptor antagonist 2)wiht naisea(CTCAE Grade2) at register 3)judge to be not suitable by the attending physycian

Design outcomes

Primary

Measure	Time frame
CR rate in overall phase(6 daays after chemotherapy)	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026